Intergroup collaboration in ovarian cancer: a giant step forward

The rather slow evolution of so-called "optimal chemotherapy" for ovarian c ancer is the result of suboptimal randomised clinical trials, not having th e statistical power to identify truly superior regimens, and of the lack of systematic comparisons of new agents with relevant control arms. There is little doubt that we need international collaboration to move the field for ward in a timely and coherent manner. European and transatlantic collaborat ion represents the beginning of the process and point to the success that c an await us if the drive to work together remains strong. A similar organis ation as for breast cancer (Breast International Group, BIG) needs to be es tablished for ovarian cancer.